NeuroSearch of Copenhagen says it will go ahead with plans to study an experimental therapy (formerly in the pipeline for Alzheimer's and Parkinson's) after Boehringer Ingelheim dropped its rights to the compound. Boehringer halted plans for a Phase III trial of NS2330 after a mid-stage study failed to hit efficacy targets. Now NeuroSearch says it will study the compound's effectiveness as a treatment for obesity and Type 2 diabetes in a Phase II trial slated to begin later this year. It hopes to proceed with a new partner on the drug, though the drug developer gave no indications of who that might be.
- read this AFX article [1] for more information
Links:
[1] http://www.forbes.com/home/feeds/afx/2006/01/25/afx2474823.html